Abstract
One of the key receptors involved in the prothrombotic stage of an acute coronary syndrome (ACS) is platelet glycoprotein VI (GPVI). This constitutively expressed collagen receptor is platelet-specific and has shown to be a useful biomarker tool for the early detection of atheroslerotic diseases such as ACS and ischemic stroke. In a multimarker panel of several biomarkers, platelet GPVI may contribute to risk stratification and prediction of clinical outcome in patients with symptomatic atherosclerotic diseases. Moreover, the soluble receptor of GPVI may also be an interesting and prospective target for molecular imaging to identify sites of vulnerable plaques as the results of preclinical studies suggest. Apart from the diagnostic use of platelet as well as soluble, plasmatic GPVI, therapeutical implications may be the blockade of collagen binding sides of GPVI, as platelet GPVI is not able to bind to collagen where the binding sides were already saturated with soluble GPVI. This therapeutic aspect could serve as a promising strategy for antithrombotic and antiatherosclerotic therapy in future.
Keywords: Platelets, platelet and soluble glycoprotein vi, biomarker, plaque imaging, antithrombotic therapy, molecular imaging, diagnosis, structure, regulation, knockout mice
Current Drug Targets
Title: Platelet and Soluble Glycoprotein VI - Novel Applications in Diagnosis and Therapy
Volume: 12 Issue: 12
Author(s): Boris Bigalke, Margitta Elvers, Tanja Schonberger and Meinrad Gawaz
Affiliation:
Keywords: Platelets, platelet and soluble glycoprotein vi, biomarker, plaque imaging, antithrombotic therapy, molecular imaging, diagnosis, structure, regulation, knockout mice
Abstract: One of the key receptors involved in the prothrombotic stage of an acute coronary syndrome (ACS) is platelet glycoprotein VI (GPVI). This constitutively expressed collagen receptor is platelet-specific and has shown to be a useful biomarker tool for the early detection of atheroslerotic diseases such as ACS and ischemic stroke. In a multimarker panel of several biomarkers, platelet GPVI may contribute to risk stratification and prediction of clinical outcome in patients with symptomatic atherosclerotic diseases. Moreover, the soluble receptor of GPVI may also be an interesting and prospective target for molecular imaging to identify sites of vulnerable plaques as the results of preclinical studies suggest. Apart from the diagnostic use of platelet as well as soluble, plasmatic GPVI, therapeutical implications may be the blockade of collagen binding sides of GPVI, as platelet GPVI is not able to bind to collagen where the binding sides were already saturated with soluble GPVI. This therapeutic aspect could serve as a promising strategy for antithrombotic and antiatherosclerotic therapy in future.
Export Options
About this article
Cite this article as:
Bigalke Boris, Elvers Margitta, Schonberger Tanja and Gawaz Meinrad, Platelet and Soluble Glycoprotein VI - Novel Applications in Diagnosis and Therapy, Current Drug Targets 2011; 12 (12) . https://dx.doi.org/10.2174/138945011797635867
DOI https://dx.doi.org/10.2174/138945011797635867 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiac Applications for Human Pluripotent Stem Cells
Current Pharmaceutical Design Fibrosis as a Therapeutic Target Post-Myocardial Infarction
Current Pharmaceutical Design Oncolytic Coxsackievirus and the Mechanisms of its Effects on Cancer: A Narrative Review
Current Cancer Therapy Reviews New Chemotherapeutic Strategies Against Malaria, Leishmaniasis and Trypanosomiases
Current Medicinal Chemistry Investigational Positive Inotropic Agents for Acute Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Heme Oxygenase-1/CO as Protective Mediators in Cigarette Smoke- Induced Lung Cell Injury and Chronic Obstructive Pulmonary Disease
Current Pharmaceutical Biotechnology Drug Uptake Systems in Liver and Kidney
Current Drug Metabolism Electrochemical Study of DNA Damaged by Oxidation Stress
Combinatorial Chemistry & High Throughput Screening Green Tea Catechins and Cardiovascular Health: An Update
Current Medicinal Chemistry MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts Apoptosis via Inhibiting Nemo-like Kinase (NLK)
Current Pharmaceutical Design Pharmacokinetic Considerations of Perinatal Antiretroviral Therapy
Current Drug Metabolism Sudden Unexplained Death in Infancy and Long QT Syndrome
Current Pediatric Reviews Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor
Current Vascular Pharmacology Pulmonary Arterial Hypertension in HIV-infected Patients
Current Hypertension Reviews Functions of Fukutin, a Gene Responsible for Fukuyama Type Congenital Muscular Dystrophy, in Neuromuscular System and Other Somatic Organs
Central Nervous System Agents in Medicinal Chemistry Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Functional Variants of the Interleukin-23 Receptor Gene in Non-Gastrointestinal Autoimmune Diseases
Current Medicinal Chemistry Recent Patents on Epilepsy Genetics
Recent Patents on DNA & Gene Sequences Gluten-dependent Intestinal Autoimmune Response
Current Pharmaceutical Design Stem Cell Pharmacogenomics
Current Topics in Medicinal Chemistry